Immuron Reports Continued Sales Growth

Rhea-AI Summary

Immuron (NASDAQ: IMRN) reported continued unaudited sales growth for Travelan® in H1 FY26 with global H1 sales of AUD$4.2 million, up 5% on the prior comparative period. Key regional results included Australia H1 AUD$3.3 million, +13%; USA H1 AUD$0.9 million, +17%; and Canada H1 AUD$56 thousand, -85% while Canada Q2 recovered +191% quarter-on-quarter. Growth in Australia and the U.S. was attributed to expanded digital/social marketing, promotions, new store listings and increased travel; a one-off reduction in stock holdings from the merged Sigma Healthcare/Chemist Warehouse group offset some Australian gains. ProIBS® launched in Australia before Christmas and is listed with two of three major pharmacy wholesalers and five banner groups.

Positive

• Global H1 sales AUD$4.2M, +5% on pcp
• Australia H1 sales AUD$3.3M, +13% on pcp
• USA H1 sales AUD$0.9M, +17% on pcp
• Canada Q2 sales +191% on prior quarter
• ProIBS® launched early and listed in five banner groups

Negative

• Canada H1 sales AUD$56k, down 85% on pcp
• One-off stock reduction from merged Sigma Healthcare/Chemist Warehouse group offset Australian growth
• Launch timing close to year end limited initial ProIBS® rollout opportunities

Key Figures

Global H1 sales: AUD$4.2 million Global Q2 sales: AUD$2.2 million Australia H1 sales: AUD$3.3 million +5 more

8 metrics

Global H1 sales AUD$4.2 million H1 sales, up 5% on prior comparative period

Global Q2 sales AUD$2.2 million Q2 sales, up 11% on prior quarter

Australia H1 sales AUD$3.3 million H1 sales, up 13% on prior comparative period

USA H1 sales AUD$0.9 million H1 sales, up 17% on prior comparative period

Canada H1 sales AUD$56 thousand H1 sales, down 85% on prior comparative period

Canada Q2 sales AUD$42 thousand Q2 sales, up 191% on prior quarter

Q1 FY26 sales AUD$2.0 million Q1 FY26 unaudited sales from prior update

ATM capacity US$17,847,954 US$15M ATM plus US$2,847,954 extension over three years

Market Reality Check

Price: $0.9770 Vol: Volume 53,751 is below th...

low vol

$0.9770 Last Close

Volume Volume 53,751 is below the 20-day average of 84,571, suggesting limited pre-news positioning. low

Technical Shares at $1.06 are trading below the 200-day MA $1.70 and 55.65% under the 52-week high.

Peers on Argus

IMRN was down 0.93% while highlighted biotech peers showed mixed moves, from -17...

IMRN was down 0.93% while highlighted biotech peers showed mixed moves, from -17.57% (ADAP) to +3.93% (XTLB), pointing to stock-specific dynamics rather than a broad sector trend.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Defense award & trial	Positive	-10.9%	DoD-funded program and Travelan clinical timeline update.
Nov 05	FDA IND approval	Positive	-12.7%	FDA IND clearance enabling Phase 2 IMM-529 trial.
Oct 31	Clinical update	Positive	-5.9%	IMM-529 review status and Travelan P2TD timing change.
Oct 13	Sales update	Positive	+0.5%	Q1 FY26 sales growth across Australia and U.S.
Oct 08	IND submission	Positive	+2.7%	Submission of IND to FDA for IMM-529 Phase 2 trial.

Pattern Detected

Recent positive clinical and growth updates often coincided with negative price reactions, indicating a pattern of selling into good news.

Recent Company History

Over the last few months, Immuron reported multiple clinical and commercial milestones. On Oct 8, 2025, it submitted an IND for IMM-529 with Phase 2 plans and cited potential US$400M annual revenue, followed by an FDA IND approval on Nov 5, 2025. Travelan clinical updates and a U.S. Department of Defense-funded program were announced on Oct 31 and Dec 3, 2025. Commercially, Q1 FY26 unaudited sales reached AUD$2.0M with strong Australia and U.S. growth. Today’s H1 sales growth release extends that commercial momentum theme.

Market Pulse Summary

This announcement highlights continued Travelan® sales growth, with global H1 revenue of AUD$4.2 mil...

Analysis

This announcement highlights continued Travelan® sales growth, with global H1 revenue of AUD$4.2 million and solid double‑digit gains in Australia and the U.S., alongside early ProIBS® launch progress. Historical updates show a mix of clinical advances and commercial expansion, but also funding activity and regional variability like Canada. Investors may watch subsequent quarters for sustained growth across regions, execution on new listings, and any further capital-raising developments.

Key Terms

gastrointestinal (gi) tract, hyper-immune bovine antibodies, travelers’ diarrhea, australian register for therapeutic goods, +1 more

5 terms

gastrointestinal (gi) tract medical

"targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract."

The gastrointestinal (GI) tract is the body’s continuous tube—mouth to anus—that digests food, absorbs nutrients and expels waste, including the stomach, small and large intestines and related organs. Investors care because many drugs, medical devices and diagnostics target GI conditions; treatments that succeed can create steady sales and change cost or reimbursement patterns, much like fixing a clogged pipe improves flow in a home plumbing system and reduces downstream problems.

hyper-immune bovine antibodies medical

"Travelan® is a purified tablet preparation of hyper-immune bovine antibodies and other factors,"

Hyper-immune bovine antibodies are concentrated infection-fighting proteins collected from cows that have been deliberately vaccinated or exposed so their milk, especially first milk, is rich in antibodies targeted at a specific disease-causing agent. Investors track these products because they can be turned into treatments, preventive supplements, or diagnostic tools—like harvesting a crop bred for one trait—and their value depends on clinical results, regulatory approval, manufacturing scale and market demand.

travelers’ diarrhea medical

"reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder"

An acute intestinal illness caused by ingesting contaminated food or water while traveling, producing loose stools, stomach cramps, nausea and sometimes fever that typically lasts a few days. Investors care because outbreaks can dent tourism and business travel, boost demand for treatments and diagnostics, and disrupt workforces or clinical trials—like a sudden travel-delay that interrupts revenue and raises short-term costs for companies across travel, healthcare and consumer sectors.

australian register for therapeutic goods regulatory

"listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709)"

The Australian Register for Therapeutic Goods (ARTG) is the official government list of medical products—like medicines, vaccines, and medical devices—approved for supply in Australia. For investors, an entry on this register is like a product getting a legal green light to be sold and marketed there, signalling reduced regulatory risk and clearer market access which can affect a company’s sales potential and valuation.

natural health product regulatory

"In Canada, Travelan® is a licensed natural health product (NPN 80046016)"

A natural health product is a consumable item made from vitamins, minerals, herbs, probiotics or other naturally derived ingredients sold to support health, such as dietary supplements, herbal remedies or certain traditional medicines. Investors care because these products are treated differently from drugs by regulators—meaning different safety, labeling and approval rules—which affects how quickly products can reach market, the size of potential sales, and the legal and reputational risk a company faces.

AI-generated analysis. Not financial advice.

Sales Highlights (unaudited):

Global	H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter
Australia	H1 sales AUD$3.3 million up 13% on prior comparative period (pcp) Q2 sales AUD$1.7 million up 11% on prior quarter Australian launch of ProIBS®
Canada	H1 sales AUD$56 thousand down 85% on prior comparative period (pcp) Q2 sales AUD$42 thousand up 191% on prior quarter
USA	H1 sales AUD$0.9 million up 17% on prior comparative period (pcp) Q2 sales AUD$0.4 million up 8% on prior quarter

MELBOURNE, Australia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan^®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Continued Travelan^® H1 sales growth (+11% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing; (2) same store growth as a result of increased promotion and past promotions driving new customers and return customers respectively; (3) growth from new stores within banner groups in which we secured core ranging in FY25; (4) increased South East Asian travel. These growth factors were offset by a one-off reduction of stock holding by the merged Sigma Healthcare/Chemist Warehouse group.

Although it is difficult launching close to year end, we managed to launch ProIBS^® (https://investors.immuron.com.au/announcements/7225649) prior to Christmas ahead of schedule to gain some early opportunities. ProIBS^® is stocked by two of the three largest pharmacy wholesalers with listings in five banner groups. 2026 category reviews provide us with the opportunity for additional listings. We believe that once Australian consumers try ProIBS^®, they will love it!

H1 sales in the U.S. increased (+17% on pcp) on the back on number of marketing initiatives including: (1) improved Travelan^® store on Amazon.com; (2) local U.S. Travelan^® Facebook and Instagram pages; (3) increased paid social, influencer and organic social media marketing.

During FY25 we had a Q1 pipeline fill into over a thousand Canada retail doors on the back of securing listings within key pharmacy and grocery retail groups. As expected, sales picked up on the back of consumer promotions in Q2 FY26 (+191% on prior quarter). We anticipate a continued increase in pull through from stores as we continue to build Travelan^® brand awareness within Canada though our in-store educational programs, in-store promotions, and social media marketing.

Travelan^® will be launched into Jean Coutu pharmacies in 3QFY26. Jean Coutu is the number one or two pharmacy group in Quebec, the second largest province in Canada by population.

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT: Steven Lydeamore Chief Executive Officer steve@immuron.com

About Travelan^®
Travelan^® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan^® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler’s diarrhea. In Australia, Travelan^® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler’s Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan^® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler’s Diarrhea. In the U.S., Travelan^® is sold as a dietary supplement for digestive tract protection.

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

Immuron Platform Technology
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Sign up to Immuron’s Investor Hub: Here

FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/576036f2-3c0a-4722-bbfc-02dd4072e96e

FAQ

What were Immuron (IMRN) global H1 Travelan® sales in H1 FY26?

Immuron reported global H1 Travelan® sales of AUD$4.2 million, a 5% increase on the prior comparative period.

How did Travelan® perform in Australia for H1 FY26 for IMRN?

Australia H1 Travelan® sales were AUD$3.3 million, up 13% versus the prior comparative period.

What caused the U.S. sales increase for IMRN Travelan® in H1 FY26?

U.S. H1 sales rose 17%, attributed to an improved Amazon store, local social pages, and increased paid and influencer marketing.

Why did Canada H1 sales for IMRN decline while Q2 improved sharply?

Canada H1 was AUD$56k, down 85% on pcp, but Q2 rose 191% quarter-on-quarter after retail listings and consumer promotions.

What is ProIBS® status for Immuron (IMRN) in Australia?

ProIBS® was launched before Christmas and is stocked by two of three major pharmacy wholesalers with listings in five banner groups.

Did any distribution issues affect IMRN Travelan® sales in H1 FY26?

Yes; a one-off reduction in stock holding by the merged Sigma Healthcare/Chemist Warehouse group offset some Australian sales growth.